ARS Pharmaceuticals, Inc. (SPRY) Reports In-Line Q2 EPS
Tweet
Share
E-mailARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q2 EPS of ($0.46), in-line with the analyst estimate of ($0.46). Revenue for the quarter came in at $15.72 million versus the consensus estimate of $13.77 million.
For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
